A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Patidegib (Primary)
  • Indications Chondrosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2012 Status changed from recruiting to discontinued, according to an Infinity Pharmaceuticals media release.
    • 02 Jun 2012 Additional lead trial investigator identified as reported by Oregon Health and Science University Institutional Review Board.
    • 26 May 2012 Planned number of patients changed from 140 to 169 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top